STENTYS : Reports First Quarter 2015 Revenues Rose 28% (16 April 2015)

 Change in quarterly revenues*

*Unaudited

STENTYS recorded a remarkable sales performance during the first quarter of 2015, compared to a year ago, with strong revenue growth of 28% to €1.1 million. The growth was driven by the launch of the self-apposing Sirolimus-eluting stent, STENTYS SES, which obtained CE mark at the end of October 2014 and whose geographical deployment is underway. STENTYS SES accounted for 68% of first quarter 2015 sales, while the product it is replacing, the paclitaxel-eluting stent, accounted for just 16% of sales during the period.

"The significant acceleration in revenues from a year ago shows the excellent positive reception from cardiologists to our self-apposing Sirolimus-eluting stent. We anticipate the ramp up will continue in European countries where we have a direct sales force and in other regions of the world where we market through local distributors. In

2015, the acceleration in sales should also be reinforced by the launch of MiStent SES® as well as our new delivery catheter."

 Upcoming financial press release

STENTYS expects to publish its revenues for the first half of 2015 on July 8, 2015.

STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS' Self- Apposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition

problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very

low one year mortality rate and a faster arterial healing compared to conventional stents. The company's product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS' commercial network in Europe, the Middle East, Asia and Latin America. More information is available at www.stentys.com.

This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company's
present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward- looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 "Risk Factors" of the Company's 2013 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers on October 29,
2014 under number D.14-1026 as such section may be updated from time to time.

STENTYS Stanislas Piot CFO

Tel.: +33 (0)1 44 53 99 42 stan.p@stentys.com

NewCap

Investor Relations / Strategic Communications
Dusan Oresansky / Pierre Laurent
Tel.: +33 (0)1 44 71 94 93 stentys@newcap.fr

LifeSci Advisors LLC

Andrew McDonald
Tel: +1.646.597.6987 andrew@lifesciadvisors.com
STENTYS is listed on Comp. B of the Euronext Paris market
ISIN: FR0010949404 - Ticker: STNT

Page 1 of 1

distributed by